Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials
about
An update on clinical utility of rilpivirine in the management of HIV infection in treatment-naïve patientsFactors associated with pre-treatment HIV RNA: application for the use of abacavir and rilpivirine as the first-line regimen for HIV-infected patients in resource-limited settings.Novel approaches to HIV therapy.Single-Tablet Regimens in HIV TherapyBurden of nonnucleoside reverse transcriptase inhibitor resistance in HIV-1-infected patients: a systematic review and meta-analysisHIV-associated lipodystrophy: impact of antiretroviral therapy.Once-Daily, Single-Tablet Regimens For the Treatment of HIV-1 InfectionActive pharmaceutical ingredients for antiretroviral treatment in low- and middle-income countries: a survey.A consensus statement on the renal monitoring of Australian patients receiving tenofovir based antiviral therapy for HIV/HBV infection.Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2014, Thailand.Multicenter study of skin rashes and hepatotoxicity in antiretroviral-naïve HIV-positive patients receiving non-nucleoside reverse-transcriptase inhibitor plus nucleoside reverse-transcriptase inhibitors in Taiwan.Low Frequency of Drug-Resistant Variants Selected by Long-Acting Rilpivirine in Macaques Infected with Simian Immunodeficiency Virus Containing HIV-1 Reverse Transcriptase.Adherence to Antiretroviral Therapy and Virologic Failure: A Meta-AnalysisRilpivirine inhibits drug transporters ABCB1, SLC22A1, and SLC22A2 in vitroPopulation Pharmacokinetics and Pharmacogenetics Analysis of Rilpivirine in HIV-1-Infected Individuals.Outcomes in older versus younger patients over 96 weeks in HIV-1- infected patients treated with rilpivirine or efavirenz in ECHO and THRIVE.Rilpivirine: drug profile of a second-generation non-nucleoside reverse transcriptase HIV-inhibitor.Has the time come to abandon efavirenz for first-line antiretroviral therapy?Effectiveness and safety of rilpivirine, a non-nucleoside reverse transcriptase inhibitor, in treatment-naive adults infected with HIV-1: a meta-analysis.Pharmacokinetic drug evaluation of dolutegravir plus rilpivirine for the treatment of HIV.Novel Antiretroviral Drugs in Patients with Renal Impairment: Clinical and Pharmacokinetic Considerations.The problem of renal function monitoring in patients treated with the novel antiretroviral drugs.Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-Infected adults treated with rilpivirine or Efavirenz for 96 weeks in the ECHO and THRIVE trials.Improvement of lipid profiles when switching from efavirenz to rilpivirine in HIV-infected patients with dyslipidemia.Rilpivirine Pharmacokinetics Without and With Darunavir/Ritonavir Once Daily in Adolescents and Young Adults.Evaluation of the Aptima(®) HIV-1 Quant Dx assay for HIV-1 RNA viral load detection and quantitation in plasma of HIV-1-infected individuals: A comparison with Abbott RealTime HIV-1 assay.Moving forward with treatment options for HIV-infected children.Single-Tablet Emtricitabine-Rilpivirine-Tenofovir as HIV Postexposure Prophylaxis in Men Who Have Sex With Men.Selection of Rilpivirine-Resistant HIV-1 in a Seroconverter From the SSAT 040 Trial Who Received the 300-mg Dose of Long-Acting Rilpivirine (TMC278LA).Deep sequencing analysis of HIV-1 reverse transcriptase at baseline and time of failure in patients receiving rilpivirine in the phase III studies ECHO and THRIVE.Safety, tolerability and pharmacokinetics of rilpivirine following administration of a long-acting formulation in healthy volunteers.Pharmacokinetic interaction between etravirine or rilpivirine and telaprevir in healthy volunteers: A randomized, two-way crossover trial.Discontinuation of tenofovir disoproxil fumarate for presumed renal adverse events in treatment-naïve HIV-1 patients: meta-analysis of randomized clinical studies.Switching from tenofovir/emtricitabine and nevirapine to a tenofovir/emtricitabine/rilpivirine single-tablet regimen in virologically suppressed, HIV-1-infected subjects.Week 96 analysis of rilpivirine or efavirenz in HIV-1-infected patients with baseline viral load ≤ 100 000 copies/mL in the pooled ECHO and THRIVE phase 3, randomized, double-blind trials.Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens.Impact of food and different meal types on the pharmacokinetics of rilpivirine.Key Factors Influencing the Emergence of Human Immunodeficiency Virus Drug Resistance in Low- and Middle-Income Countries.Dolutegravir plus rilpivirine dual therapy in treating HIV-1 infection.MDR1 and BCRP Transporter-Mediated Drug-Drug Interaction between Rilpivirine and Abacavir and Effect on Intestinal Absorption.
P2860
Q26827791-BB1F33FE-F5BB-457C-B069-B35DD0BA7C40Q33644568-163566AC-0ED7-43E8-8CB7-C01E2EF614ACQ33777819-028A37EB-1F20-4C2F-AA5D-3205BB9B935EQ33939110-609AA8BE-CD1F-47EF-A83E-FBD9A176AA43Q33988153-069A314B-6219-42AF-9198-164A37D966AAQ34655845-525BB33F-3F89-4CB0-9D2C-E171BB682126Q34976284-5B6CAAA9-A25D-4650-ADA8-9C5602AD186EQ35053803-9954D6B1-680D-4117-B114-DC0B506EB2AFQ35149475-342FCF35-4450-4D03-A810-44224A9E0FCBQ35530299-8B4171EB-F7A9-4110-81C4-4345E7A146D7Q36286145-62554BEF-A9EC-453E-BCE1-3B72996F7105Q36290753-7CCB8141-CD8D-4FDF-881A-8D1F8776AA86Q36822464-8387980C-4ADD-4EEB-B93E-D9DA579C88B5Q37263486-AB1E556D-66A7-4137-9CDF-A8BF11BD70C3Q37538683-D7F5CADE-32F3-44A5-886C-1651A75BE529Q37651634-12A6A6A9-14A4-48A0-B48F-1A23D37A1263Q38168930-AD1438A0-F229-4D28-8B5C-EEF416B438F2Q38194051-CC4CEDAA-BFFF-40F1-BA04-F4A8B635DCB1Q38272654-1D94595E-B614-4B93-8D3C-F16E910BB36FQ38601891-2C6AC349-B36C-4957-8F6D-4DD8E28F244BQ39074109-B92D791B-3E6D-4069-B882-452DE6D83DC0Q39203030-FD587059-8F5A-4583-A2B8-718CE1797354Q39515202-6097B180-BCEA-4F9C-91D1-D6F3AFED0820Q39519582-FAF7282E-1E8E-43B4-8C54-838DA9CDF463Q39760086-59E9D73A-8763-42C5-9E65-16EED7C66EB7Q40007100-2A2579B6-DE93-4442-B61D-7FE84D803BE6Q40063042-BADBA1E7-41EF-465B-AAD2-33496169F986Q40292568-F95E6E93-33E2-4D65-9C8F-3A6875B10CFCQ40911924-4D5FAAD9-A562-4610-90AF-97E192AC83C4Q40978625-B9813740-5950-4DA2-82E4-C317CB312397Q41219268-EB20B603-2468-4CFC-ACF7-F17BF188E7C7Q41230514-FC955C10-B73E-4A39-85DC-9CB95978C6FBQ41643193-6CDA8483-0A2A-432B-9DCC-2B8FA1646DA4Q42211662-A97D1DC5-8519-4BB1-855E-5437B758E3DEQ42249739-4B7D8FAE-32B4-4949-AAAD-77AACA9A2B30Q42260844-78CF8122-629D-4CF6-A8CF-8B529E8C346CQ42261088-36277504-2E2B-4A1E-B225-2EEEC491FB15Q45323778-6701B157-D1B9-46B5-95C1-230C0FECEA75Q47301806-D94FC25C-E72B-4F4E-9A2C-2E60DC9AD27AQ48145638-1252AB95-572D-4FAE-92ED-6AC9A56636B9
P2860
Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials
description
article
@en
im März 2013 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в березні 2013
@uk
name
Week 96 efficacy and safety of ...... wo Phase III randomized trials
@en
Week 96 efficacy and safety of ...... wo Phase III randomized trials
@nl
type
label
Week 96 efficacy and safety of ...... wo Phase III randomized trials
@en
Week 96 efficacy and safety of ...... wo Phase III randomized trials
@nl
prefLabel
Week 96 efficacy and safety of ...... wo Phase III randomized trials
@en
Week 96 efficacy and safety of ...... wo Phase III randomized trials
@nl
P2093
P1433
P1476
Week 96 efficacy and safety of ...... wo Phase III randomized trials
@en
P2093
Calvin J. Cohen
Frank Rhame
Hans-Jürgen Stellbrink
Herta Crauwels
Isabel Cassetti
Jean-Michel Molina
Katia Boven
Laurence Rimsky
Peter Williams
Ploenchan Chetchotisakd
P304
P356
10.1097/QAD.0B013E32835CEE6E
P407
P577
2013-03-01T00:00:00Z